SummaryInsulin-like growth factor binding protein-3 is a transforming growth factor-β--responsive gene that is regulated transcriptionally by GAIP interacting protein C-terminus. It promotes hepatic stellate cell migration through integrin and protein kinase B dependent pathway leading to portal hypertension in vivo.

Hepatic stellate cells (HSCs) drive liver fibrosis via their activation into myofibroblasts, which are contractile, proliferative, motile, and deposit extracellular matrix.[@bib1]^,^[@bib2] Molecules involved in HSC activation such as transforming growth factor-β (TGF-β) and its corresponding receptors[@bib3] have been studied extensively, but exact mechanisms still remain only partially understood, which has hindered appropriate drug development.[@bib4], [@bib5], [@bib6] This study and other previous studies have shown that GIPC is a scaffold protein that regulates transmembrane-receptor signaling including TGF-β receptor.[@bib7] As a downstream signaling molecule, GIPC plays an important role in signaling transduction.[@bib8] Our understanding on how TGF activates HSC through GIPC and novel targets is a gap in knowledge and a focus of our current study.

Insulin-like growth factor binding protein 3 (IGFBP-3) is 1 of the 6 known IGFBPs.[@bib9] The liver is one of the major sources of circulating IGFBP-3, which shows growth-inhibitory properties by blocking interaction between IGF1/2 and its receptor.[@bib10]^,^[@bib11] IGFBP-3 also has been shown to affect cell function by IGF-receptor--independent signaling pathways.[@bib12], [@bib13], [@bib14], [@bib15] Furthermore, IGFBP-3 is implicated in HSC activation based on gene expression profiling studies from quiescent and activated HSCs.[@bib16] Inhibition of HSC activation has been shown to prevent IGFBP-3 transcription in vitro and in vivo.[@bib16] However, additional information pertaining to IGFBP-3 and liver fibrosis beyond this correlative information is not available.

To explore liver fibrosis targets downstream of TGF-β and GIPC in a nonbiased manner, we performed sequential RNA sequencing studies. Our initial messenger RNA (mRNA) sequencing analysis of TGF-β in HSCs identified IGFBP-3 as one of the top downstream targets. Furthermore, in our second mRNA sequencing screening, IGFBP-3 was identified further as one of the top targets of GIPC. Based on this information we further explored the following: (1) the mechanism by which TGF-β and GIPC activate IGFBP-3 gene transcription, (2) effects of IGFBP-3 on liver fibrosis in vivo, and (3) mechanisms of effect of IGFBP-3 on HSCs in vitro. We show that GIPC knockdown decreases TGF-β--induced IGFBP-3 expression through epigenetic modifications of histone 3 lysine K27 (H3K27) within the IGFBP-3 promoter. Global knockdown of IGFBP-3 attenuates portal hypertension and liver fibrosis in the bile duct ligation (BDL) and carbon tetrachloride (CCl~4~) murine models. Moreover, IGFBP-3 levels in the serum from patients with cirrhotic livers are significantly higher than levels from normal livers. Finally, IGFBP-3 promotes HSC activation through an integrin--Protein Kinase B (AKT) signaling pathway. Our findings show a novel mechanism of HSC regulation mediated by IGFBP-3, and may provide a potential therapeutic target in the treatment of liver fibrogenesis and portal hypertension.

Results {#sec1}
=======

RNA Sequencing Identifies a Gene Network in HSCs That Includes IGFBP-3 as an Important Target Gene of TGF-β {#sec1.1}
-----------------------------------------------------------------------------------------------------------

TGF-β is one of the most potent promoters for HSC activation. However, mechanisms of this activation only partially are understood. To evaluate novel downstream targets of TGF-β signaling, we performed mRNA sequencing analysis of HSC stimulated with TGF-β for 48 hours compared with nonstimulated HSCs ([Figure 1](#fig1){ref-type="fig"}*A*). Ingenuity pathway analysis of the top up-regulated and down-regulated genes showed hepatic fibrosis/hepatic stellate cell activation as the top signaling pathway based on --log *P* values ([Figure 1](#fig1){ref-type="fig"}*B*). Unexpectedly, using this nonbiased approach, we identified IGFBP-3 as one of the top targets of TGF-β within the hepatic fibrosis pathway alongside the expected canonical TGF-β--induced genes for collagen (COL8A1, COL7A1, COL5A1, COL4A2, COL4A1, COL3A1, COL1A1, and COL16A1), α-smooth muscle actin 2, and fibronectin ([Figure 1](#fig1){ref-type="fig"}*C*). The increase of IGFBP-3 in both cell lysates and culture media was confirmed by Western blot (WB) ([Figure 1](#fig1){ref-type="fig"}*D*). This RNA sequencing data pointed us toward IGFBP-3 as a target warranting further interrogation.Figure 1**The hepatic fibrosis/HSC activation pathway is the most highly regulated pathway by TGF-β treatment through transcriptomic analysis.** (*A*) Cultured human HSCs (hHSCs) were serum-starved overnight and treated with vehicle and TGF-β. Cells were harvested and mRNA was collected and samples were submitted to NextGen (Mayo Clinic, Rochester, MN) sequencing core for library preparation and sequencing after an initial quality-control check. A heat map of whole-genome gene expression shows the differences in the expression profile between vehicle- and TGF-β--treated hHSCs, which were run in triplicate, of all genes with a log fold change \> 1.5 and \< -1.5. (*B* and *C*) Ingenuity pathway analyses (Qiagen) showed that the fibrotic pathway was regulated differentially between the groups. Regulation of specific genes within the hepatic fibrosis/HSC activation pathway are shown, with IGFBP-3 highlighted in the *red outlined rectangles*. (*D*) Immunoblot of IGFBP-3 from hHSCs serum-starved overnight and treated with TGF-β for 48 hours showed an increase in the production of IGFBP-3. Both cell lysates and conditioned media were collected to detect IGFBP-3 (cellular and secreted proteins are shown in duplicate). GAPDH was used as a loading control. Results are from 3 independent experiments. The Student unpaired, 2-tailed *t* test was used to analyze the differences between groups for statistical significance. ∗*P* \< .05. diffexp, differential expression; rpkm, Million mapped reads.

IGFBP-3 Up-regulation in Response to TGF-β Is Dependent on the Scaffold Protein GIPC {#sec1.2}
------------------------------------------------------------------------------------

Recently, our group identified the scaffold protein GIPC as an important molecule in membrane-receptor signaling and HSC activation.[@bib7] To investigate the role of GIPC as a possible regulator of TGF-β--induced IGFBP-3 expression in HSCs, we performed a second mRNA sequencing analysis of HSCs with a knockdown of GIPC vs controls stimulated with TGF-β as early as 2 hours ([Figure 2](#fig2){ref-type="fig"}*A*). By using ingenuity pathway analysis, again we identified hepatic fibrosis/hepatic stellate cell activation as the top signaling pathway blocked by GIPC knockdown ([Figure 2](#fig2){ref-type="fig"}*B*). Within this pathway, IGFBP-3 also was identified as one of the top targets of GIPC alongside α-smooth muscle actin 2, collagen (COL11A2, COL15A1, COL4A1, COL5A3), platelet-derived growth factor receptors α and β (PDGFRα and β), PDGFD, and serpine1 ([Figure 2](#fig2){ref-type="fig"}*C*). Given the novelty of IGFBP-3 compared with other well-characterized fibrogenic proteins identified from sequencing, we subsequently focused our mechanistic studies on IGFBP-3.Figure 2**The hepatic fibrosis/HSC activation pathway is the most highly regulated pathway by GIPC knock down in HSCs.** (*A*) GIPC was knocked down in cultured human HSCs using lentiviral-mediated short hairpin RNA. Cells were serum-starved overnight and treated with vehicle and TGF-β for 2 hours. mRNA was collected and samples were submitted to NextGen sequencing core (Mayo Clinic, Rochester, MN) for library preparation and sequencing. Differences in the expression profile between control and GIPC knockdown human HSCs with TGF-β treatment are shown in the heat map of whole-genome gene expression. Samples were run in triplicate, of all genes with a logFc \> 1.5 of \< -1.5. (*B* and *C*) Ingenuity pathway analyses (Qiagen) showed that the HSC activation/fibrotic pathway was regulated differentially by GIPC. Regulation of specific genes within the hepatic fibrosis/HSC activation pathway are shown. Top pathway and IGFBP3 are highlighted in the *red outlined rectangles*. KD, knockdown; ILK, integrin-linked kinase.

IGFBP-3 Is Expressed Predominantly in HSCs {#sec1.3}
------------------------------------------

Because IGFBP-3 is a secreted protein, we first identified the cellular source of IGFBP-3 in the liver. HSCs emerged as the top liver cell type with increased IGFBP-3 expression via quantitative polymerase chain reaction (qPCR) analysis ([Figure 3](#fig3){ref-type="fig"}*A*). Single-cell RNA sequencing analysis from mouse liver from olive oil or CCl~4~ treatment showed clusters of nonparenchymal liver cells with enhanced IGFBP-3 expression along with other HSC marker genes such as COL1A1 and PDGFRβ in the same cluster 10 ([Figure 3](#fig3){ref-type="fig"}*B* and *C*), suggesting that IGFBP-3 is expressed mainly in HSCs in both basal and CCl~4~ activation conditions.Figure 3**IGFBP-3 is expressed prominently in HSCs.** (*A*) qPCR from various hepatic and nonhepatic cell lines shows higher mRNA levels of IGFBP-3 in human HSCs (hHSCs) compared with other cell lines. One-way analysis of variance with Bonferroni multiple comparison tests was used to analyze groups for statistical significance. ∗*P* \< .05. (*B*) Heat map of HSC cluster marker genes labeled on the *top* from mouse liver cells undergo olive oil and CCl~4~ treatment. *Columns* denote genes; *rows* denote clusters. (*C*) Clustering of cells from mouse liver treated with olive oil and CCl~4~. Cluster 10 represents HSCs with a high expression of COL1A1, PDGFRβ, and IGFBP-3. Exp, Exponent; HUH7, hepatocyte-derived carcinoma cell line; HUVEC, human umbilical vein endothelial cell; H69, human lung small-cell carcinoma cell line.

IGFBP-3 Expression and Release Is Decreased Both In Vitro and In Vivo After GIPC Knockdown {#sec1.4}
------------------------------------------------------------------------------------------

To establish and investigate the relationship between GIPC and IGFBP-3, we sought to explore further the effects of GIPC knockdown and to confirm the results found in the RNA sequencing analysis. By using qPCR, enzyme-linked immunosorbent assay (ELISA) and WB, we detected a significant down-regulation of both IGFBP-3 mRNA and protein levels in HSCs after GIPC knockdown ([Figure 4](#fig4){ref-type="fig"}*A* and *B*). Furthermore, decreased IGFBP-3 levels in the cell media indicated a reduced protein release after GIPC knockdown ([Figure 4](#fig4){ref-type="fig"}*C*). To study the effect of GIPC knockdown on IGFBP-3 in vivo, we used mice carrying floxed GIPC alleles, which were crossed with animals that express Cre under the COL1A1 promotor, which generated mouse lines with HSC-selective deletion of GIPC (referred to as *Col*^*cre*^*/GIPC*^*fl/fl*^). Prior studies showed that these mice developed attenuation of liver fibrosis in response to chronic CCl~4~ administration.[@bib7] Herein, we clearly found a significant reduction in IGFBP-3 release to the serum ([Figure 4](#fig4){ref-type="fig"}*D*). Both hepatic IGFBP-3 mRNA and protein levels were decreased in Col^cre^/GIPC^fl/fl^ mice compared with controls. Taken together, these experiments showed that GIPC promotes IGFBP-3 production and release.Figure 4**IGFBP-3 transcription and expression is regulated by GIPC.** (*A*) GIPC was knocked down in human HSCs and cells were harvested for mRNA analysis. GIPC knockdown human HSCs showed a reduction in the mRNA levels of IGFBP-3. (*B*) Conditioned media was collected from serum-starved human HSCs with and without GIPC knockdown and was analyzed for IGFBP-3 secreted from the cells. Reduced IGFBP-3 production from human HSCs was observed on GIPC knockdown using ELISA and WB. (*C*) Immunoblot from cell lysates showed efficiency of GIPC knockdown, GAPDH was used as a loading control. (*D*) WB was performed from serum of GIPC^fl/fl^ and Col^cre^/GIPC^fl/fl^ mice that received olive oil or CCl~4~ injections intraperitoneally twice weekly for 4 weeks. IGFBP-3 was increased in serum from CCl~4~-treated GIPC^fl/fl^ mice but not in Col^cre^/GIPC^fl/fl^ mice. All data are shown as means ± SEM. One-way analysis of variance with the Bonferroni multiple comparison tests were used to analyze groups for statistical significance. The Student unpaired *t* test was used to analyze the differences between 2 groups. ∗*P* \< .05. shRNA, short hairpin RNA.

IGFBP-3 Expression Is Regulated by GIPC Through H3K27 Acetylation and Methylation of the IGFBP-3 Promoter {#sec1.5}
---------------------------------------------------------------------------------------------------------

Gene expression is regulated commonly by P300 and histone modification at lysine 27 acetylation (H3K27Ac, leading to gene activation), and histone trimethylation at lysine 27 (H3K27m3), resulting in gene repression by enhancer of zeste homologue 2 (EZH2).[@bib17] Studies with human melanoma and hepatocellular carcinoma cell lines have further implicated a role for histone acetylation in IGFBP-3 expression.[@bib18], [@bib19], [@bib20], [@bib21] Our investigation of the ENCODE TFBS database ([encode.org](http://encode.org){#intref0010}) suggested that there are 2 overlapping EZH2 binding sites in the human IGFBP-3 transcription start site region (human genome browser \[hg19\], chromosome 7 \[chr7\]:45959379-45960659/chr7:45959718-45961110), and another at the promoter region (hg19 chr7:45961121-45962023). Based on this rationale, we designed primers to pursue chromatin-immunoprecipitation (ChIP) experiments in primary human HSC with a lentiviral-based knockdown of GIPC and IGFBP-3--promoter luciferase assays to explore the relationship of GIPC with the inhibitory H3K27me3 epigenetic mark on the IGFBP-3 gene locus and IGFBP-3 transcription activity, respectively. ChIP analysis showed that knockdown of GIPC increased H3K27me3 repression marks on the IGFBP-3 gene locus while decreasing H3K27Ac ([Figure 5](#fig5){ref-type="fig"}*A* and *B*). Accordingly, nuclear protein expression of H3K27m3 increased, whereas that of H3K27Ac was reduced ([Figure 5](#fig5){ref-type="fig"}*C*). We further examined for H3K27Ac with a pharmacologic inhibitor. H3K27Ac inhibition was achieved with chemical inhibition using compound cAMP-responsive element binding protein binding protein30, which is a potent cAMP-responsive element binding protein binding protein/p300 (the major histone acetyltransferase to affect H3K27Ac level) BRD inhibitor.[@bib22] As expected, TGF-β--induced IGFBP-3 mRNA levels in HSCs were reduced after p300 inhibition ([Figure 5](#fig5){ref-type="fig"}*D*). These results indicate that GIPC regulates IGFBP-3 transcription through H3K27m3 suppression and H3K27Ac activation.Figure 5**Knockdown of GIPC in human HSCs leads to decreased IGFBP-3 gene transcription via histone modifications.** (*A*) ChIP using H3K27me3 antibody showed increased methylation of histone H3 at lysine 27 of the IGFBP-3 promoter after GIPC knockdown. (*B*) There was reduced acetylation of histone H3 at lysine 27 in GIPC knockdown human HSCs as shown by ChIP using the H3K27Ac antibody. (*C*) Lysates from human HSCs with GIPC knockdown showed increase levels of methylation of histone H3 at lysine 27 by WB. A reduction in acetylation of histone H3 at lysine 27 was observed in GIPC knockdown human HSCs compared with control cells. The efficiency of short hairpin RNA (shRNA)-mediated knockdown of GIPC also was shown with GAPDH as a loading control. (*D*) qPCR for IGFBP-3 from serum-starved human HSCs treated with cAMP-responsive element binding protein binding protein-30 (p300 inhibitor) showed a reduction in mRNA levels of IGFBP-3 after p300 inhibition. TGF-β treatment was used as a positive control. (*E*) IGFBP-3 promoter luciferase reporter plasmids were used in promoter analysis. Two sets of IGFBP-3 promoters were used; pGL3-IGFBP-3 full length (FL) (-3595 bp to +55 bp) and pGL3-IGFBP-3-deletion (Del) (-1950 bp to +55 bp). Constructs were transfected into human HSCs with and without GIPC knockdown, and luciferase activity was measured. GIPC silencing in human HSCs led to a significant reduction of activity of both promoter constructs. All data are shown as means ± SEM. One-way analysis of variance with Bonferroni multiple comparison tests were used to analyze groups for statistical significance. ∗*P* \< .05.

Next, we aimed to investigate the effect of GIPC knockdown on luciferase-reporter activity. HSCs with GIPC knockout showed a 90% reduction in promoter activity ([Figure 5](#fig5){ref-type="fig"}*E*). Next, we performed a promoter analysis using the following 2 IGFBP-3 promoter luciferase reporter plasmids: pGL3-IGFBP-3 full length (-3595 base pairs \[bp\] to +55 bp) and gGL3-IGFBP-3 deletion (-1950 bp to +55 bp), which were transfected into HSCs followed by luciferase assay.[@bib23]^,^[@bib24] Luciferase activity of IGFBP-3 promoter full length and deletion showed similar down-regulation by GIPC knockdown, suggesting that +55 bp to -1950 bp of the IGFBP-3 transcription start site may contain an EZH2 binding motif and may be required for H3K27m3 repression induced by GIPC knockdown. Taken together, our data show that GIPC\`s effect on IGFBP-3 occurs through histone modification and transcriptional regulation on IGFBP-3 promoter.

Global Knockout of IGFBP-3 Attenuates HSC Activation In Vivo {#sec1.6}
------------------------------------------------------------

Given the effects of IGFBP-3 on HSC activation and migration, we aimed to investigate if global knockout of IGFBP-3 results in attenuation of HSC activation markers in vivo. For this purpose, we used mice with deletion of both alleles of the IGFBP-3 gene (referred to as IGFBP-3^-/-^). BDL surgery was used to induce liver fibrosis. Portal pressure, Sirius red staining, hepatic collagen content, and α-smooth muscle actin (αSMA) were lower in IGFBP-3^-/-^ mice compared with genotype control mice 4 weeks after BDL surgery ([Figure 6](#fig6){ref-type="fig"}*A--D*). IGFBP-3 levels were increased in the serum of wild-type (WT) mice after BDL surgery ([Figure 6](#fig6){ref-type="fig"}*E*), but not in IGFBP-3^-/-^ mice. We next used CCl~4~ as a second model of liver fibrosis. IGFBP-3^-/-^ mice showed attenuated up-regulation of SMA in response to CCl~4~ compared with WT mice in response to CCl~4~ ([Figure 7](#fig7){ref-type="fig"}*A*). Serum IGFBP-3 levels were increased in mice after CCl~4~-induced liver fibrosis, but not in IGFBP-3^-/-^ mice ([Figure 7](#fig7){ref-type="fig"}*B*). Next, we isolated HSCs from WT and IGFBP-3^-/-^ mice. HSCs derived from IGFBP-3^-/-^ mice showed less culture-induced activation after 72 hours compared with WT mice as indicated by αSMA mRNA levels ([Figure 7](#fig7){ref-type="fig"}*C*). IGFBP-3 knockout was confirmed as well by qPCR ([Figure 7](#fig7){ref-type="fig"}*D*).Figure 6**IGFBP-3**^**-/-**^**mice are protected from BDL-induced fibrosis and portal hypertension.** (*A*) Liver injury was induced in WT and IGFBP-3^-/-^ mice by BDL. IGFBP-3^-/-^ mice showed lower portal pressure after BDL surgery compared with WT mice. (*B*) Liver sections from IGFBP-3^-/-^ mice after BDL surgery show lower Sirius red staining compared with WT mice. (*C*) Collagen content was reduced in IGFBP-3^-/-^ mice compared with WT mice after BDL surgery as measured by a hepatic hydroxyproline assay. (*D*) αSMA levels were lower in IGFBP-3^-/-^ mice compared with WT mice after BDL surgery by WB. (*E*) Serum levels of IGFBP-3 were quantified by ELISA from WT and IGFBP-3^-/-^ mice after sham and BDL. IGFBP-3 levels in serum were increased in BDL compared with sham mice, whereas IGFBP-3^-/-^ mice had no IGFBP-3 detected. All data are shown as means ± SEM. Each *dot* in the scatter plot indicates an individual animal in each of the panels. One-way analysis of variance with Bonferroni multiple comparison tests were used to analyze groups for statistical significance. ∗*P* \< .05, ∗∗*P* \< .001, ∗∗∗*P* \< .0001.Figure 7**IGFBP-3**^**-/-**^**mice show attenuated HSC activation in response to chronic CCl**~**4**~**.** (*A*) IGFBP-3^-/-^ or genotype control mice were injected with olive oil or CCl~4~ intraperitoneally to induce liver fibrosis. αSMA levels were lower in IGFBP-3^-/-^ mice after chronic CCl~4~ administration compared with control mice by WB of whole-liver lysates. Densitometric analysis also is shown. (*B*) ELISA shows an increase in serum levels of IGFBP-3 in CCl~4~-administered mice and loss of IGFBP-3 protein in serum from IGFBP-3^-/-^ mice. (*C*) HSCs isolated from IGFBP-3^-/-^ and WT mice were used to detect the mRNA level of αSMA by qPCR. (*D*) IGFBP-3 knockout was confirmed by qPCR. (*E*) WB from serum of patients with cirrhosis showed increased levels of IGFBP-3 compared with controls. All data are shown as means ± SEM. Each *dot* in the scatter plot indicates an individual animal in each of the panels. One-way analysis of variance with Bonferroni multiple comparison tests were used to analyze groups for statistical significance. ∗*P* \< .05, ∗∗*P* \< .001, ∗∗∗*P* \< .0001.

IGFBP-3 Expression Is Up-regulated in Patients With Alcoholic Cirrhosis {#sec1.7}
-----------------------------------------------------------------------

To gain insight into the role of IGFBP-3 in human cirrhosis, we analyzed serum and liver samples from 6 patients with alcoholic cirrhosis. IGFBP-3 serum levels were detected by WB and compared with healthy controls (n = 6). IGFBP-3 levels were increased significantly ([Figure 7](#fig7){ref-type="fig"}*E*). Taken together, these data indicate up-regulation of IGFBP-3 in cirrhosis, highlighting its possible role in human liver fibrogenesis including its potential use as a therapeutic target.

IGFBP-3 Promotes HSC Migration via β1 Integrin Signaling and the Phosphatidylinositol 3-Kinase / Protein Kinase B Pathway, Which Requires Iron (Fe^3+^) as Co-factor {#sec1.8}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------

Finally, we moved to in vitro studies to ascertain the mechanism of effect of IGFBP-3 on HSCs that could promote fibrosis in vivo. HSC migration is critical for HSC configuration and alignment around the sinusoids, which is required for sinusoidal contraction and perivascular matrix deposition. Therefore, we next examined the effect of IGFBP-3 on a possible HSC migration--autocrine/paracrine amplification loop. We incubated HSCs with varying concentrations of IGFBP-3 (200 and 400 ng/mL), and measured HSC migration by wound assay. This showed a dose-dependent increase by IGFBP-3 on cell migration ([Figure 8](#fig8){ref-type="fig"}*A*). These data indicate a chemokinetic effect of IGFBP-3 on HSCs.Figure 8**IGFBP-3 promotes cell migration in human HSCs in an integrin β1--dependent manner.** (*A*) Confluent monolayer of human HSCs serum-starved overnight was scratched and incubated with recombinant IGFBP-3 in a dose mentioned with the corresponding figure and images were captured. IGFBP-3 promoted cell migration in human HSCs in a concentration-dependent fashion as shown by wounding assay. Representative images are shown in the panel with quantification represented by a graph. (*B*) Recombinant human IGFBP-3 was incubated with human HSCs in a microfluidic chamber system and migration was assessed. Human HSCs were incubated with integrin β1--neutralizing antibody with and without IGFBP-3, and migration was quantified. In the presence of integrin β1--neutralizing antibody, migration was reduced in response to IGFBP-3. Quantification of migration is shown in the graph with representative images. (*C*) qPCR from human HSCs with and without IGFBP-3 knockdown showed a reduction in Ki67 mRNA, which is a marker for cell proliferation. (*D*) The efficiency of IGFBP-3 knockdown is shown. One-way analysis of variance with Bonferroni multiple comparison tests used to analyze groups for statistical significance. The Student unpaired *t* test was used to analyze the differences between 2 groups. ∗*P* \< .05. Ab, antibody.

Integrins are transmembrane proteins involved in cell adhesion and migration by linking extracellular matrix proteins to the actin cytoskeleton. IGFBP-3 has been shown to form multimolecular complexes with integrin.[@bib25]^,^[@bib26] By using a microfluidic flow chamber, we incubated HSCs with integrin β1--neutralizing antibody and then treated cells with IGFBP-3 to study migration. IGFBP-3--mediated HSC migration was blocked with integrin β1--neutralizing antibody ([Figure 8](#fig8){ref-type="fig"}*B*). We next examined the role of IGFBP-3 in cell proliferation. HSCs with IGFBP-3 knockdown showed a reduction in mRNA levels of Ki67, indicating the role of IGFBP-3 in cell proliferation as well ([Figure 8](#fig8){ref-type="fig"}*C*). IGFBP-3 knockdown also was confirmed by qPCR ([Figure 8](#fig8){ref-type="fig"}*D*). From a signaling perspective, integrin β1 can induce phosphorylation of AKT to promote cell migration. Therefore, we sought to test if IGFBP-3 may work through this signaling model to induce HSC chemokinesis and proliferation. Indeed, incubation of HSCs with increasing concentrations of IGFBP-3 (200 and 400 ng/mL) increased AKT phosphorylation as assessed by WB from HSC lysates ([Figure 9](#fig9){ref-type="fig"}*A*). Furthermore, AKT phosphorylation was attenuated by pre-incubation with integrin β1--neutralizing antibody 4 hours before IGFBP-3 treatment, although total AKT was not affected ([Figure 9](#fig9){ref-type="fig"}*A*). Finally, integrin and IGFBP-3 were proposed previously to form a multimolecular complex through Fe^3+^.[@bib25]^,^[@bib26] To show the involvement of Fe^3+^ in the IGFBP-3--induced AKT phosphorylation pathway, we treated HSCs with IGFBP-3 and different doses of Fe^3+^. We found that Fe^3+^ enhanced IGFBP-3--induced AKT phosphorylation in a dose-dependent manner ([Figure 9](#fig9){ref-type="fig"}*B*). Taken together, these results show that IGFBP-3 induces AKT activation through Fe^3+^--enhanced integrin β1 signaling to promote HSC migration.Figure 9**IGFBP-3 induces activation of AKT through integrin β1.** (*A*) Serum-starved human HSCs were treated with IGFBP-3 and integrin β1--neutralizing antibody and lysates were collected and analyzed for WB. Immunoblots evidenced activation of AKT by IGFBP-3, which was blocked by integrin β1--neutralizing antibody. Total AKT and GAPDH were used as a loading control. (*B*) WB from lysates of serum-starved human HSCs were treated with recombinant IGFBP-3 with and without Fe^3+^ in a dose-response fashion as indicated. The entire concentration response curve was performed in duplicate. IGFBP-3--mediated activation of AKT in human HSCs was enhanced with the addition of Fe. Total AKT and GAPDH were used as a loading control. Densitometric analysis of immunoblots is shown under the blot. All data are shown as means ± SEM. One-way analysis of variance with Bonferroni multiple comparison tests were used to analyze groups for statistical significance. ∗*P* \< .05, ∗∗∗*P* \< .0001. Ab, Antibody; pAkt, phospho protein kinase B; T-AKT, total protein kinase B.

Discussion {#sec2}
==========

In this study, genome-wide expression profile experiments were conducted and followed by examination of chromatin dynamic events that regulate expression of IGFBP-3. The use of genetically modified mice, observations in patient-derived tissue, and, finally, in vitro signaling and functional studies allowed us to link these expression profile data with pathobiologically significant phenomena. The significant findings from these comprehensive analyses are as follows: (1) GIPC increases IGFBP-3 expression in HSCs through epigenetic modification on histone proteins; (2) IGFBP-3 knockdown attenuates liver fibrosis in vivo; (3) serum levels of IGFBP-3 are up-regulated in cirrhotic patients; and (4) IGFBP-3 promotes HSC activation and migration through integrin-AKT signaling. [Figure 10](#fig10){ref-type="fig"} summarizes these key findings, which are discussed in the following sections in more detail.Figure 10**The proposed mechanism of IGFBP-3 in the regulation of HSC migration.** IGFBP-3 expression is up-regulated by GIPC through epigenetic changes characterized by a decrease of H3K27 trimethylation and a reciprocal increase in H3K27 acetylation after activation of the TGF receptor. Furthermore, IGFBP-3 promotes HSC migration by iron-enabled binding to integrin β1 and mediates AKT signaling, leading to autocrine and paracrine HSC migration. Akt, protein kinase B.

TGF-β activation of HSCs contributes to liver fibrosis.[@bib27] In this study we compared expression profiles of normal HSCs, with profiles of HSCs treated with TGF-β by mRNA sequencing. We identified IGFBP-3 as one of the top TGF-β--induced targets alongside canonical genes such as collagen and fibronectin. Given our recent insights into the role of the scaffold protein GIPC in receptor signaling and HSC activation,[@bib7] we performed another mRNA sequencing analysis of TGF-β--stimulated HSCs with GIPC knockdown. GIPC has been shown to link receptor activation with intracellular signaling and gene transcription.[@bib7] We previously showed that GIPC regulates receptor protein stability, function, and, ultimately, cell migration in HSCs.[@bib7] We now link GIPC mechanisms of action through its downstream transcriptional target IGFBP-3.

IGFBP-3 originally was identified as an IGF transport protein with multifunctional properties achieved in part by blocking the interaction between IGF 1/2 and its IGF receptor.[@bib9] Our in vitro data comparing different types of liver cell lines and our single-cell RNA sequencing data ([Figure 3](#fig3){ref-type="fig"}) are consistent with a recent single-cell RNA sequencing study,[@bib28] indicating that HSCs are the major liver cell type to produce IGFBP-3 in control mice (received olive oil) and in response to chronic CCl~4~ in mice. More importantly, 2 recent single cell RNA sequencing studies of human liver also showed that HSCs and mesenchymal cells are the major liver cell types that produce IGFBP-3.[@bib29]^,^[@bib30] Indeed, IGFBP-3 has been shown previously to activate HSCs based on gene expression profiling studies from quiescent and activated HSCs.[@bib16] The present study identifies mechanisms by which this occurs.

We show that IGFBP-3 expression and release from HSC is decreased on GIPC knockdown in vitro and in vivo. Our data indicate that GIPC can increase IGFBP-3 transcription through epigenetic changes characterized by a decrease in H3K27 trimethylation, and a reciprocal increase in H3K27 acetylation. The GIPC-induced increase in IGFBP-3 is mediated through the acetyltransferase p300, which is responsible for the acetylation of H3K27 within the promoter region of IGFBP-3. The observed histone methylation (H3K27m3) is regulated by EZH2, a methyltransferase.[@bib27] EZH2 is the functional enzymatic component of the polycomb repressive complex 2, which is responsible for the methylation activity of the polycomb repressive complex 2 on histone 3 lysine 27 (H3k27), together with other proteins required for optimal repression such as SUZ12.[@bib27]^,^[@bib31] Comparison of the luciferase activity of the truncation construct of IGFBP-3 promoter and the full length suggests that +55 bp to -1950 bp of the IGFBP-3 transcription start site indeed contains the EZH2 binding motif and may be required for H3K27m3 repression induced by GIPC knockdown. Previous studies have implicated DNA acetylation as a regulatory mechanism of IGFBP-3 as well,[@bib20]^,^[@bib21] which may complement our observations related to histone acetylation. GIPC regulates PDGFRβ expression in HSCs in a similar way to what we observed with IGFBP-3.[@bib7] Indeed, knockdown of GIPC decreases H3K27Ac and increases H3K27me3 levels to regulate PDGFRβ.[@bib7] We conclude that expression of IGFBP-3 is tightly controlled by these epigenetic modifications and these 2 key enzymes. Both enzymes therefore might be used as upstream targets to regulate IGFBP-3 as well as PDGFRβ, potentially to provide a greater therapeutic benefit.[@bib7]

Our in vivo studies have shown that global deletion of IGFBP-3 significantly reduces liver fibrosis and portal hypertension in response to chronic liver injury. Mechanistically, this raises an important question: does IGFBP-3 regulate portal hypertension only through effects on fibrosis or also through effects on vascular resistance, and, if the latter, are effects only on HSCs or also on liver sinusoidal endothelial cells (LSEC)? We did not observe an effect of IGFBP-3 on collagen mRNA levels in vitro (control siRNA 1.02 ± 0.03 vs IGFBP-3 siRNA 0.98 ± 0.02 \[fold change\] by qPCR), but we did see reduced matrix deposition in IGFBP-3^-/-^ mice exposed to chronic liver injury. Given that IGFBP-3 increased HSC migration and proliferation in vitro, we hypothesize that the effect of IGFBP-3 on fibrosis in vivo is the result of HSC mass and migration rather than transcriptional activation of collagen in HSCs. Therefore, in vivo it is likely that both increased fibrosis and increased HSC contraction of sinusoids contributes to IGFBP-3 driving portal hypertension.[@bib32] To examine for potential effects of IGFBP-3 on LSECs, murine LSECs were treated with recombinant IGFBP-3, and tube angiogenesis, a canonical function of endothelial cells, which is thought to contribute to portal hypertension,[@bib33] was examined. There was no difference in cells treated with IGFBP-3 compared with control (control 1.0 ± 0.2 vs IGFBP-3 0.95 ± 0.1 \[fold change\]). Based on these results, we propose that IGFBP-3 does not influence LSEC defects, which characterize portal hypertension, but rather its effects are on HSCs directly.

Although our proposed role of IGFBP-3 is consistent with a prior correlative study implicating IGFBP-3 with HSC activation,[@bib16] it is in contradistinction to a recent study that showed that IGFBP-3 has anti-inflammatory effects in hepatocytes.[@bib34] IGFBP-3 also has been implicated in tumor-suppressive properties in non--small-cell lung cancer, glioblastoma, and, more recently, neuroblastoma.[@bib35], [@bib36], [@bib37] These divergent effects of IGFBP-3 likely are dependent on the cell type that is both producing and responding to the molecule. For example, tumor-suppressive actions of IGFBP-3 may occur through ligand binding with IGF and IGFR.[@bib38] In hepatocytes, IGFBP-3 is thought to inhibit nuclear factor-κB and proinflammatory cytokines via IGFBP-3--receptor--mediated activation of caspases.[@bib34] Eventually, cell-selective rather than global knockout of IGFBP-3 will be useful to clarify cell-specific actions of IGFBP-3.

IGFBP-3 has been shown as a marker of HSC activation and implicated in cell migration in a variety of cell types.[@bib39], [@bib40], [@bib41] However, the mechanism by which this occurs is not clear. Our wounding assay and microfluidic models confirmed that IGFBP-3 promotes HSC migration. Signaling studies have shown that this occurs through an in integrin β1-/AKT-dependent pathway. Insulin-like growth factor-I--independent functions of IGFBP-3 may be achieved through binding with metals such as iron,[@bib41] this results in conformational changes that expose the metal binding domain epitope to enhance interaction with cell surface targets such as integrins.[@bib41] It is known that chronic liver diseases such as viral hepatitis, alcoholic liver disease, and nonalcoholic fatty liver disease are associated with increased hepatocellular, sinusoidal, or mixed-pattern iron loading.[@bib42]^,^[@bib43] The increased free iron seems to be associated with disease progression because it poses a highly reactive form, and pro-oxidant forms of iron eventually are diverted toward liver parenchymal cells, where they may fuel oxidative damage.[@bib44] Indeed, we found that Fe^3+^ enhances IGFBP-3--induced AKT phosphorylation in an integrin- and dose-dependent manner. Our finding extends the role of iron in IGFBP-3 function, which is independent from IGF. It is interesting to speculate that iron/IGFBP-3 interactions could contribute to the potential hepatotoxicity of iron in vivo.[@bib45]

In the present study, we show that IGFBP-3 promotes HSC migration by iron-enabled binding to integrin β1--mediating AKT signaling. Global deletion of IGFBP-3 also attenuates liver fibrosis and portal hypertension in vivo. These findings provide evidence that the aforementioned increased serum IGFBP-3 levels and increased IGFBP-3 expression in the mesenchymal cell cluster of single-cell RNA sequencing, detected in cirrhotic patients,[@bib30] may indeed be of functional relevance and make IGFBP-3 an interesting biomarker[@bib46] or target for antifibrotic treatment.

Methods {#sec3}
=======

Cell Lines and Transfection {#sec3.1}
---------------------------

Human primary HSCs (catalogue 5300; ScienCell Research Laboratories, Carlsbad, CA) were cultured in Dulbecco\'s modified Eagle medium supplemented with 10% fetal bovine serum and penicillin/streptomycin. Experiments were performed after overnight serum starvation. Small interfering RNA (siRNA) for IGFR, integrin β1, and IGFBP-3 were purchased from Qiagen (Venlo, The Netherlands). GIPC short hairpin RNAs were a gift from Dr Mukhopadhyay (Mayo Clinic, Rochester, MN) and purchased from Sigma-Aldrich (NM_005716.2-1083s1c1, NM_005716.2-1045s1c1; St. Louis, MO). Lentiviral transduction of short hairpin RNA was performed by incubation with viral particles for 48 hours in Dulbecco\'s modified Eagle medium with 10% fetal bovine serum and polybrene, followed by selection with puromycin for 24 hours.

Compounds and Ligands {#sec3.2}
---------------------

IGFBP-3 and IGF1 were purchased from Sigma-Aldrich and used at concentrations of 200 and 400 ng/mL, respectively, in basal media overnight unless otherwise stated in the Figure legends 8 and 9. AKT inhibitor and cAMP-responsive element binding protein binding protein30 (p300 inhibitor) were used at a dilution of 1:1000. PDGF-BB (R&D Systems, Minneapolis, MN) was used at a concentration of 10 ng/mL.

Antibodies {#sec3.3}
----------

Primary antibodies were used at a concentration of 1:1000 (except for glyceraldehyde-3-phosphate dehydrogenase \[GAPDH\], for which the dilution was 1:5000) in 5% dry milk/Tris-buffered saline/1% Tween 20 with overnight incubation at 4°C. Secondary antibodies (donkey anti-rabbit + horseradish peroxidase or sheep anti-mouse + horseradish peroxidase) were used at a concentration of 1:1000 (except for GAPDH, for which the secondary antibody was used at a dilution of 1:3000) for 1 hour at room temperature in Tris-buffered saline/1% Tween 20. Membranes were developed with luminol solution. Primary antibodies for IGFBP-3, IGFR, phosphorylated IGFR, phosphorylated AKT, phosphorylated extracellular signal-regulated kinase, H3K27Ac, and H3K27m3 all were purchased from Cell Signaling Technology (Danvers, MA). GAPDH was purchased from Sigma Aldrich, and GIPC antibody was purchased from Proteus Bioscience (Ramona, CA).

RNA Isolation, Complementary DNA Synthesis, and Quantitative Real-Time PCR {#sec3.4}
--------------------------------------------------------------------------

\'Total RNA was extracted from HSCs according to the manufacturer\'s instructions using an RNeasy kit (Qiagen), and 5 μg RNA was used for complementary DNA synthesis with oligo (deoxythymine) primer using the SuperScript III first-strand synthesis system for reverse-transcription PCR (Invitrogen, Carlsbad, CA) per the manufacturer's protocol. Real-time PCR was performed in a total 25-μL volume reaction using Sybr Green Master Mix and the 7500 real-time PCR system (both from Applied Biosystems, NY), according to the manufacturer\'s instructions. Reverse-transcription PCR analysis was performed with the following primer sets: human GIPC forward: 5′- GCTGGAGAGTTACATGGGTATC-3′; human GIPC reverse: 5′-TCAGGGAAGGCAAAGTCAC-3′; mouse GIPC forward: 5′- GAAGGTGGATGACTTGCTAGAG-3′; and mouse GIPC reverse: 5′-TCATCTGGGAATGCGAAGTC -3′; and human IGFBP-3 forward: 5′-GCGGCCGCATGGGGACTTCCCATCC-3′; human IGFBP-3 reverse: 5′-CTCGAGCAGGAAGCTGTCTTCCACC-3′. Amplification of human GAPDH and mouse β-actin was performed in the same reaction for respective samples as internal controls. Each experiment was performed in triplicate.

RNA Sequencing and Analysis {#sec3.5}
---------------------------

mRNA sequencing libraries were prepared and sequenced on an llumina (Mayo Clinic, Rochester, MN) HiSeq 2000 instrument at the Mayo Clinic Center for Individualized Medicine Medical Genomics Facility. Sequence reads from RNA sequencing samples were aligned to the human genome hg19 and gene annotations from Refseq gene using TopHat v2.05. Cufflinks v2.0.2 was used to calculate FPKM values of genes. Differential gene expression was analyzed by Cuffdiff using a cut-off false-discovery rate of less than 0.05, and an absolute value of logFC ≥ 2. Single-cell RNA sequencing has been done with liver cells including hepatic stellate cells from control and CCl4 mice for barcoding and sequencing in NGS core at Mayo Clinic Rochester MN as per 10X Genomics protocol (https://www.10xgenomics.com/single-cell-technology/). The hepatic stellate cells clusters were analyzed by Loupe cell browser in this article.

ChIP Analysis {#sec3.6}
-------------

ChIP was performed with EZ-Magna ChIP (catalog \#17-408; Millipore, Burlington, MA) with specific immunoprecipitating antibodies including H3K27Me3 or H3K27Ac, with the negative control normal rabbit IgG as previously described.[@bib7] Cells were cross-linked with 1% formaldehyde, after which they were lysed and subjected to sonication, then sheared cross-linked to fragment DNA. After centrifugation, the supernatant was diluted in ChIP buffer. Samples subsequently were incubated with 5 μg antibody and ChIP-grade Protein A magnetic beads (Millipore) overnight at 4°C. After extensive washing (Low Salt, High Salt, LiCI Immune Complex Wash Buffer, and TE Buffer; Sigma-Aldrich Inc, St. Louis, MO), chromatin was eluted, and DNA was purified and analyzed by qPCR. Fold enrichment was calculated by first normalizing ChIP-qPCR to input DNA of the target gene as a percentage of input. This subsequently was normalized to the percentage input of a negative control gene region (intergenic region of 36Me3-hCh19) to correct for experimental variation. H3K27Ac (4279), H3K27me3 (6002), and isotype-specific IgG control (2027) were purchased from Abcam (Cambridge, MA).

Cell Migration Functional Assays {#sec3.7}
--------------------------------

HSCs were grown to a confluent monolayer in a 6-well tissue culture plate before scratch being induced with a 10-μL pipette tip. Media was changed with an appropriate stimulant at the time of scratch. Cells were imaged at 0 and 6 hours after scratch. The total area of the scratch was measured using ImageJ software (National Institutes of Health, Bethesda, MD), and the percentage of migration area was calculated by the following formula: (area time 0 h -- area time 6 h)/area time 0 h.

Microfluidic Cell Migration Imaging {#sec3.8}
-----------------------------------

A 2-cell--chamber microfluidic device was used for the cell migration experiment. Presterilized microfluidic platforms were coated initially with collagen solution (0.2 mg/mL). Both cell chambers were kept separated by sealing the microgrooves. A total of 15--20 μL of the cell suspension at a density of approximately 5000 cells/μL media was added to 1 chamber with pillars. The other chamber was used to add recombinant IGFBP-3 into media. HSCs were treated with vehicle or integrin β1--neutralizing antibody. Chambers were imaged and analyzed for cell migration as previously described.[@bib7]

Animal Studies {#sec3.9}
--------------

All animal experiments were approved by the Institutional Animal Care and Use Committee and performed in accordance with institutional guidelines. Embryos from IGFBP-3^-/-^ (insulin-like growth factor binding protein 3; targeted mutation 1, Velocigene (Igfbp3tm1(KOMP)Vlcg) were purchased from the UC-Davis (Davis, CA) mouse repository. The embryos were injected in a foster mother and subsequent progeny were mated for germline production and colony expansion. IGFBP-3^-/-^ mice (age, 8--10 wk) and background control strain mice (age matched) (C57BL/6NTac) with an initial body weight of approximately 25 g were used. GIPC^fl/fl^ mice were crossed with collagen^cre^ mice to generate GIPC^fl/fl^/collagen^cre^ mice that were genetically depleted of GIPC in myofibroblasts. Cre-negative littermate controls were used for in vivo experiments. Mice underwent a twice-weekly intraperitoneal injection of 0.5 mg/kg body weight of CCl~4~ for 6 weeks. Serum and livers were harvested at week 6 for WB, hydroxyproline assay, ELISA, and immunofluorescence as described previously.[@bib3]^,^[@bib47] Eight-week-old WT and IGFBP-3^-/-^ mice were divided into 2 groups. One group underwent BDL surgery as described previously,[@bib47] and the other group received sham surgery. After 4 weeks, portal pressure was measured before killing the mice as described previously.[@bib48] Serum and livers were collected for hydroxyproline, WB, ELISA, and immunofluorescence. IGFBP-3 levels were measured in serum by the mouse IGFBP-3 Quantikine ELISA kit (R&D Systems, Inc) according to the manufacturer's instructions, and by a SpectraMax Plus 384 microplate reader (Molecular Devices, San Jose, CA).

Clinical Samples {#sec3.10}
----------------

Serum of control and alcoholic cirrhotic patients were collected and analyzed by WB to detect IGFBP-3 proteins. Clinical and demographic information about this cohort was published recently.[@bib7] Patient studies were approved by the Institutional Review Board at the Mayo Clinic (Rochester, MN).

Statistics {#sec3.11}
----------

Experiments were performed at least 3 independent times and numeric data are expressed as means ± SEM. The significance of the differences of the means was evaluated by a paired and unpaired 2-tailed Student *t* test. A *P* value less than .05 was considered significant.

Study Approval {#sec3.12}
--------------

All animal experiments were approved by the IACUC and performed in accordance with institutional guidelines (Mayo Clinic). Patient sample use was approved by the Institutional Review Board at the Mayo Clinic.
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